For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it

Sponsorship complete. Dine on...

Nutrition, wellness, weight loss, and calmer healthy living.

Eli Lilly's Retatrutide Shows Promising Weight Loss Results for Type 2 Diabetes Patients

Oct 1, 2026
Eli Lilly's Retatrutide Shows Promising Weight Loss Results for Type 2 Diabetes Patients

Eli Lilly’s highly anticipated GLP-1 drug retatrutide has shown promising results in helping individuals with Type 2 diabetes achieve substantial weight loss, with participants losing up to 60 pounds, or approximately 23% of their body weight, based on late-stage trial results published in The Lancet. This outcome represents the most significant weight loss ever recorded in a drug trial targeting diabetes patients, a demographic that typically faces challenges in weight management.

In comparison, previous clinical trials for other medications such as semaglutide and tirzepatide reported weight losses of up to 10% (21 pounds) and 15% (34 pounds), respectively. It is important to note that these comparisons are not direct, as the drugs were not evaluated in head-to-head trials.

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it

Sponsorship complete. Dine on...

Dr. Susan Spratt, an endocrinologist and senior medical director for the Population Health Management Office at Duke Health in North Carolina, remarked that retatrutide represents a significant advancement in diabetes care, stating, "It rivals gastric bypass surgery without the surgery." Many diabetes medications, including insulin, are known to contribute to weight gain, which can be discouraging for patients striving to manage their diabetes effectively.

The trial involved over 1,110 participants, who had an average starting weight of around 234 pounds and an average body mass index (BMI) of approximately 38. Participants were randomly assigned to receive one of three weekly doses of retatrutide or a placebo over an 80-week period. By the conclusion of the trial, more than half of the participants achieved a BMI below 30, the threshold for obesity.

Additionally, results from another trial published in the New England Journal of Medicine indicated that retatrutide helped patients without Type 2 diabetes, who are classified as obese or overweight, lose up to 70 pounds, or 25% of their body weight on average, after 80 weeks. This trial also included a subset of patients with severe obesity, who lost up to 85 pounds, or 30% of their body weight, after 104 weeks, marking the most significant weight loss recorded in a medication trial and comparable to outcomes seen with bariatric surgery.

Retatrutide functions by mimicking a hormone known as GLP-1. Its unique classification as a "triple agonist" distinguishes it from Lilly’s tirzepatide, which is a "double agonist" that mimics two hormones (GLP-1 and GIP). Retatrutide adds a third hormone, glucagon, to its mechanism of action.

While Lilly has not yet submitted retatrutide for approval to the Food and Drug Administration (FDA), the trial results have positioned it as one of the most anticipated treatments in the pharmaceutical industry, with plans for an approval filing expected early next year.

However, unauthorized versions of retatrutide are already being produced and sold through various wellness platforms, med spas, and compounding pharmacies, often labeled as "for research use only"—a legal loophole that allows these compounds to be marketed without proper approval. Lilly has initiated legal action against companies distributing unapproved versions of the drug.

In addition to weight loss, retatrutide has shown potential benefits in reducing the severity of sleep apnea and alleviating knee arthritis pain. Earlier data also suggests that the drug may have positive effects on heart health.

The latest trial results indicate that retatrutide effectively lowers blood sugar levels in patients with diabetes, achieving reductions in A1C levels—an important measure of average blood sugar levels over the preceding two to three months—by up to 1.6%, compared to just 0.2% with a placebo. Notably, up to 40% of trial participants achieved an A1C level below 5.7%, which is below the cutoff for diabetes and prediabetes.

Dr. Michelle Ponder, an assistant professor of medicine at Duke University School of Medicine, expressed enthusiasm about the retatrutide data, noting that an A1C level of 5.7% indicates that diabetes may have entered remission. However, she cautioned that retatrutide could be overly potent for some patients, particularly those with mild diabetes or only slightly elevated weight. Such patients might be better suited for existing medications like Ozempic or Mounjaro. She also highlighted that switching medications can lead to changes in the frequency of side effects.

Common side effects associated with retatrutide were similar to those experienced with other GLP-1 medications, with patients primarily reporting mild to moderate symptoms such as diarrhea, nausea, constipation, and vomiting. Approximately 8% of participants taking the highest dose discontinued the drug, compared to about 5% of those on the placebo.

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it
Vegetable Prep & Salad Spinners
Taste it

Sponsorship complete. Dine on...

For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it
Kitchen Scales

Kitchen scales for recipes that deserve more precision than 'that looks about right.'

Taste it
Meal Prep Containers

Give tomorrow's lunch a proper home. Containers for meals worth looking forward to.

Taste it
Vegetable Prep & Salad Spinners

Salad spinners and vegetable-prep tools for everyday salads, bowls, and side dishes. A little less kitchen setup, a little more time to enjoy the meal.

Taste it
Blenders & Smoothie Tools

Blenders for fruit, yogurt, soups, and the combinations you actually enjoy. Everyday kitchen tools, not a promise in a glass.

Taste it
Sheet Pans & Roasting Essentials

Sheet pans and roasting racks for vegetables and simple oven meals. Useful equipment for dinner without an elaborate production.

Taste it

Sponsorship complete. Dine on...

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)